BACKGROUND: In Africa, up to 30% of HIV-infected patients who are clinically eligible for antiretroviral therapy (ART) do not start timely treatment. We assessed the effects of an intervention targeting prevalent health systems barriers to ART initiation on timing and completeness of treatment initiation. METHODS: In this stepped-wedge, non-blinded, cluster-randomised controlled trial, 20 clinics in southwestern Uganda were randomly assigned in groups of five clinics every 6 months to the intervention by a computerised random number generator. This procedure continued until all clinics had crossed over from control (standard of care) to the intervention, which consisted of opinion-leader-led training and coaching of front-line health workers, a point-of-care CD4 cell count testing platform, a revised counselling approach without mandatory multiple pre-initiation sessions, and feedback to the facilities on their ART initiation rates and how they compared with other facilities. Treatment-naive, HIV-infected adults (aged ≥18 years) who were clinically eligible for ART during the study period were included in the study population. The primary outcome was ART initiation 14 days after first clinical eligibility for ART. This study is registered with ClinicalTrials.gov, number NCT01810289. FINDINGS:Between April 11, 2013, and Feb 2, 2015, 12 024 eligible patients visited one of the 20 participating clinics. Median CD4 count was 310 cells per μL (IQR 179-424). 3753 of 4747 patients (weighted proportion 80%) in the intervention group had started ART by 2 weeks after eligibility compared with 2585 of 7066 patients (38%) in the control group (risk difference 41·9%, 95% CI 40·1-43·8). Vital status was ascertained in a random sample of 208 patients in the intervention group and 199 patients in the control group. Four deaths (2%) occurred in the intervention group and five (3%) occurred in the control group. INTERPRETATION: A multicomponent intervention targeting health-care worker behaviour increased the probability of ART initiation 14 days after eligibility. This intervention consists of widely accessible components and has been tested in a real-world setting, and is therefore well positioned for use at scale. FUNDING: National Institute of Allergy and Infectious Diseases (NIAID) and the President's Emergency Fund for AIDS Relief (PEPFAR).
RCT Entities:
BACKGROUND: In Africa, up to 30% of HIV-infectedpatients who are clinically eligible for antiretroviral therapy (ART) do not start timely treatment. We assessed the effects of an intervention targeting prevalent health systems barriers to ART initiation on timing and completeness of treatment initiation. METHODS: In this stepped-wedge, non-blinded, cluster-randomised controlled trial, 20 clinics in southwestern Uganda were randomly assigned in groups of five clinics every 6 months to the intervention by a computerised random number generator. This procedure continued until all clinics had crossed over from control (standard of care) to the intervention, which consisted of opinion-leader-led training and coaching of front-line health workers, a point-of-care CD4 cell count testing platform, a revised counselling approach without mandatory multiple pre-initiation sessions, and feedback to the facilities on their ART initiation rates and how they compared with other facilities. Treatment-naive, HIV-infected adults (aged ≥18 years) who were clinically eligible for ART during the study period were included in the study population. The primary outcome was ART initiation 14 days after first clinical eligibility for ART. This study is registered with ClinicalTrials.gov, number NCT01810289. FINDINGS: Between April 11, 2013, and Feb 2, 2015, 12 024 eligible patients visited one of the 20 participating clinics. Median CD4 count was 310 cells per μL (IQR 179-424). 3753 of 4747 patients (weighted proportion 80%) in the intervention group had started ART by 2 weeks after eligibility compared with 2585 of 7066 patients (38%) in the control group (risk difference 41·9%, 95% CI 40·1-43·8). Vital status was ascertained in a random sample of 208 patients in the intervention group and 199 patients in the control group. Four deaths (2%) occurred in the intervention group and five (3%) occurred in the control group. INTERPRETATION: A multicomponent intervention targeting health-care worker behaviour increased the probability of ART initiation 14 days after eligibility. This intervention consists of widely accessible components and has been tested in a real-world setting, and is therefore well positioned for use at scale. FUNDING: National Institute of Allergy and Infectious Diseases (NIAID) and the President's Emergency Fund for AIDS Relief (PEPFAR).
Authors: Michael J Mugavero; Andrew O Westfall; Anne Zinski; Jessica Davila; Mari-Lynn Drainoni; Lytt I Gardner; Jeanne C Keruly; Faye Malitz; Gary Marks; Lisa Metsch; Tracey E Wilson; Thomas P Giordano Journal: J Acquir Immune Defic Syndr Date: 2012-12-15 Impact factor: 3.731
Authors: Elizabeth L Corbett; Beauty Makamure; Yin Bun Cheung; Ethel Dauya; Ronnie Matambo; Tsitsi Bandason; Shungu S Munyati; Peter R Mason; Anthony E Butterworth; Richard J Hayes Journal: AIDS Date: 2007-02-19 Impact factor: 4.177
Authors: Bruce A Larson; Kathryn Schnippel; Alana Brennan; Lawrence Long; Thembi Xulu; Thapelo Maotoe; Sydney Rosen; Ian Sanne; Matthew P Fox Journal: AIDS Res Treat Date: 2013-07-16
Authors: Andrew Zolopa; Janet Andersen; William Powderly; Alejandro Sanchez; Ian Sanne; Carol Suckow; Evelyn Hogg; Lauren Komarow Journal: PLoS One Date: 2009-05-18 Impact factor: 3.240
Authors: Mary Clare Masters; Karen M Krueger; Janna L Williams; Lindsay Morrison; Susan E Cohn Journal: Expert Rev Clin Pharmacol Date: 2019-12 Impact factor: 5.045
Authors: Aaloke Mody; Izukanji Sikazwe; Angella Sandra Namwase; Mwanza Wa Mwanza; Theodora Savory; Annie Mwila; Lloyd Mulenga; Michael E Herce; Keith Mweebo; Paul Somwe; Ingrid Eshun-Wilson; Kombatende Sikombe; Laura K Beres; Jake Pry; Charles B Holmes; Carolyn Bolton-Moore; Elvin H Geng Journal: Lancet HIV Date: 2021-10-14 Impact factor: 12.767
Authors: Matthew A Spinelli; Hyman M Scott; Eric Vittinghoff; Albert Y Liu; Alicia Morehead-Gee; Rafael Gonzalez; Monica Gandhi; Susan P Buchbinder Journal: J Acquir Immune Defic Syndr Date: 2018-11-01 Impact factor: 3.731
Authors: Michael S Saag; Constance A Benson; Rajesh T Gandhi; Jennifer F Hoy; Raphael J Landovitz; Michael J Mugavero; Paul E Sax; Davey M Smith; Melanie A Thompson; Susan P Buchbinder; Carlos Del Rio; Joseph J Eron; Gerd Fätkenheuer; Huldrych F Günthard; Jean-Michel Molina; Donna M Jacobsen; Paul A Volberding Journal: JAMA Date: 2018-07-24 Impact factor: 56.272